Exome Asset Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Exome Asset Management’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-172,883	Closed	-$1.55M	–	76
2025 Q2	$1.55M	Buy	172,883 +112,283	+185%	+$1.05M	1.15%	40
2025 Q1	$455K	Buy	+60,600	New	+$489K	0.4%	45
2024 Q4	–	Sell	-196,500	Closed	-$1.49M	–	66
2024 Q3	$1.49M	Buy	+196,500	New	+$1.49M	1.01%	44

Other funds holding BCRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Exome Asset Management's BCRX Position: Q3 2025 in Review

Exome Asset Management sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2025, closing a stake of 172,883 shares — an estimated $1.55M sold.

Exome Asset Management first reported a position in BCRX in Q3 2024 and held it in 3 quarters. The position peaked at $1.55M in Q2 2025. 286 funds tracked by Wall St. Rank hold BCRX as of Q3 2025.

Exome Asset Management reported no remaining BioCryst Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Exome Asset Management sold 172,883 BioCryst Pharmaceuticals shares in Q3 2025, an estimated $1.55M.
Exome Asset Management first reported a position in BioCryst Pharmaceuticals in Q3 2024 and held it in 3 quarters.
Exome Asset Management's BioCryst Pharmaceuticals position peaked at $1.55M in Q2 2025.
286 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2025.

Based on Exome Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.